DSRLF
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | 0.90 | $576M | $162M |
| 2025 Q2 | 0.88 | $306M | $48M |
| 2025 Q1 | 0.96 | $313M | $71M |
| 2024 Q4 | 0.87 | $309M | $21M |
| 2024 Q3 | 0.84 | $287M | $131M |
| 2024 Q2 | 0.94 | $300M | $55M |
| 2024 Q1 | 0.86 | $289M | $75M |
| 2023 Q4 | 0.90 | $302M | $40M |